Steven Boyd, Director, 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 510,000 shares at $0.70 ($345K) on 2022-03-04, disclosed to the SEC on 2022-03-07.
Open-market purchase of $344k AVTX by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.71 | 50,000 | $36K | 10.3% |
| 2 | $0.70 | 135,000 | $95K | 27.4% |
| 3 | $0.66 | 325,000 | $215K | 62.3% |
| Total | $0.68 avg | 510,000 | $345K | 100% |
| Filing → |
| CERC | BUY | 2021-08-18 | $194K | — | Filing → |
| EYEG | SELL | 2021-07-29 | $27.9M | — | Filing → |
| RSLS | SELL | 2021-06-22 | $28.5M | — | Filing → |